Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Basis of Presentation and Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Warrants

Warrants	6 Months Ended
Jun. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	8. Warrants The Company recognized $237,768 and $477,183 in warrant expense for the three and six months ended June 30, 2021, respectively, included in selling, general and administration expense.

Warrants

6 Months Ended

Jun. 30, 2022

Warrants and Rights Note Disclosure [Abstract]

The Company recognized $237,768 and $477,183 in warrant expense for the three and six months ended June 30, 2021, respectively, included in selling, general and administration expense.